PVR and breast cancer: CD112+ and CD155+ macrophages were more frequently expressed in NSCLC aspirates, and with a trend also in PC aspirates, while the third TIGIT ligand, PVRL4, was in the majority expressed by macrophages from BC and PC aspirates.